|
STAR Introduction
STAR Background
STAR-At-A Glance
STAR Enrollment Statistics
STAR Images
STAR Participant Advisory Board
(PAB)
STAR Publications
STAR Result Images
STAR Q and A
|
The Study of Tamoxifen and Raloxifene (STAR) is a breast cancer
prevention clinical trial designed to determine whether the osteoporosis prevention
drug raloxifene (Evista®) is as effective as tamoxifen (Nolvadex®) in reducing
breast cancer risk, with fewer side effects. The trial began enrolling participants
in July 1999 and completed enrollment in November 2004 with 19,747 postmenopausal
women at increased risk of breast cancer.
STAR Enrollment Data: Overview
- For STAR, 184,461 women went through the risk assessment process
to determine their eligibility for the trial. Of these women, 96,368 were eligible
for the trial because of their increased risk of developing breast cancer. Of those
risk-eligible women, 19,747 chose to participate.
- Of the 19,747 women who joined STAR, 1,344 were from the placebo
group of the Breast Cancer Prevention Trial (the study that compared tamoxifen to
a placebo).
- The estimated breast cancer risk of women in STAR was substantially
above the required minimum 1.66 percent risk of developing the disease within the
next five years.
|
Five Year Breast Cancer Risk |
Women in STAR Who Fell Into This Risk Category |
|
1.66 - 1.99%
|
11.0% (2,176)
|
|
2.0 - 2.99%
|
30.2% (5,962)
|
|
3.0 - 4.99%
|
31.5% (6,229)
|
|
Greater than 5.0%
|
27.2% (5,380)
|
- Women joining STAR had to have been postmenopausal and at least 35
years of age. The ages of women joining STAR:
|
Age Range |
Women in STAR Who Fell Into This Age Range |
|
35-49
|
9.2% (1,815)
|
|
50-59
|
49.7% (9,821)
|
|
60+
|
41.1% (8,111)
|
- 9.1 percent (1,792) of the women who joined STAR reported a previous
diagnosis of lobular carcinoma in situ (LCIS), a condition that is not cancer, but
which indicates an increased chance of developing invasive breast cancer.
- About half of the women who joined STAR had had a hysterectomy prior
to enrolling (51.7 percent). Women who have had a hysterectomy are not at risk for
endometrial cancer; tamoxifen can raise a woman's chance of developing that disease.
- The majority of women on STAR (71.2 percent) reported at least one
close relative with breast cancer.
- Postmenopausal women of all races and ethnic backgrounds were encouraged
to participate in STAR, and more than 6 percent of the women in STAR were from minority
groups. A total of 38,910 women from minority groups went through the risk assessment
process; 8,359 had an increased risk of breast cancer that would qualify them for
the study; and 1,301 joined the trial.
- Among African-American participants, 21,444 went through the
risk assessment process, 3,280 were risk-eligible, and 488 joined STAR. About 2.5
percent of STAR participants were African-American.
- Among Hispanic/Latina women, 7,913 went through the risk assessment
process, 1,841 were risk-eligible, and 394 joined STAR. About 2.0 percent of the
women on STAR were Hispanic/Latina.
- Among women who defined themselves as representing another minority
population, such as Native American or Asian American, 9,553 have gone through the
risk assessment process, 3,238 were risk-eligible, and 419 joined STAR. About 2.1
percent of the women on STAR were ethnic minorities other than African-American
or Hispanic/Latina.
- For comparison, the Breast Cancer Prevention Trial - the predecessor
study to STAR - had a total of 8,525 minority women go through the risk assessment
process, 2,979 were risk-eligible, and 486 joined this 13,000-woman trial (about
4 percent of participants).
STAR Enrollment Data: By State and Province
Here is a table of enrollment data categorized by U.S. state (including Puerto Rico
and the District of Columbia) and Canadian province.
|
STAR enrollment |
|
State or Province, alphabetically by postal code |
Number of STAR participants |
State or Province, alphabetically by postal code |
Number of STAR participants |
|
AB-Alberta |
145 |
MS-Mississippi |
44 |
|
AL-Alabama |
98 |
MT-Montana |
122 |
|
AR-Arkansas |
70 |
NC-North Carolina |
915 |
|
AZ-Arizona |
199 |
ND-North Dakota |
82 |
|
BC-British Columbia |
112 |
NE-Nebraska |
208 |
|
CA-California |
1,369 |
NH-New Hampshire |
40 |
|
CO-Colorado |
349 |
NJ-New Jersey |
95 |
|
CT-Connecticut |
307 |
NM-New Mexico |
87 |
|
DC-District of Columbia |
64 |
NV-Nevada |
99 |
|
DE-Delaware |
149 |
NY-New York |
808 |
|
FL-Florida |
389 |
OH-Ohio |
959 |
|
GA-Georgia |
185 |
OK-Oklahoma |
233 |
|
HI-Hawaii |
159 |
ON-Ontario |
324 |
|
IA-Iowa |
352 |
OR-Oregon |
200 |
|
ID-Idaho |
38 |
PA-Pennsylvania |
1,301 |
|
IL-Illinois |
1,108 |
PQ-Quebec |
898 |
|
IN-Indiana |
222 |
PR-Puerto Rico |
76 |
|
KS-Kansas |
337 |
SC-South Carolina |
343 |
|
KY-Kentucky |
199 |
SD-South Dakota |
161 |
|
LA-Louisiana |
146 |
TN-Tennessee |
271 |
|
MA-Massachusetts |
616 |
TX-Texas |
1,624 |
|
MB-Manitoba |
139 |
UT-Utah |
83 |
|
MD-Maryland |
302 |
VA-Virginia |
170 |
|
ME-Maine |
52 |
VT-Vermont |
79 |
|
MI-Michigan |
1,032 |
WA-Washington |
552 |
|
MN-Minnesota |
584 |
WI-Wisconsin |
388 |
|
MO-Missouri |
795 |
WV-West Virginia |
68 |
|